Treatment of melasma with platelet‐rich plasma: A self‐controlled clinical trial

• DOI: 10.1111/dth.15703
• Publication Date: 2022-07-14T02:29:12Z
• Authors: Alejandro Gonzále...; Gabino Cervantes‐...; Jonathan Matías C...; Guillermo Alonso ...; Daniel Acevedo‐Gu...; Ana Graciela Pueb...; José Antonio Cort...; Mariana Chávez‐To...; Andrea Socorro Ál...; Enrique Cervantes...; Mónica Patricia R...; Luis Raúl Pacheco...; Francisco José Ba...; Clotilde Fuentes‐...
• Keywords: Melasma

Melasma is a common circumscribed hypermelanosis of sun-exposed areas the skin. Platelet-Rich Plasma therapy has been evidenced to inhibit melanin synthesis in animals and humans. To determine effectiveness platelet-rich plasma as treatment for melasma. Twenty female patient with melasma were involved this study. The intervention included three application sessions at 15-day intervals. Patients evaluated before after treatment. Variables measured facial concentration using area severity index score, quality life scale satisfaction grade, histologic changes. Mean age was 41 ± 7 years. An initial MELASQOL score 42 14.8 final 16.6 7.2 (p = 0.008) reported; MASI 15.5 8.4 9.5 0.001), respectively. dermatoscopy examination revealed decrease pigmentation 0.001). Histopathologic improvement detected reductions cutaneous atrophy (14 [70%] vs. 11 [55%]), solar elastosis (15 [75%] vs.11 inflammatory infiltrate (9 [45%] 6 [30%]), treatment, associated decreased intensity patch improved skin quality, shown by scores.